These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 7537799)

  • 1. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
    Fennelly D; Schneider J; Spriggs D; Bengala C; Hakes T; Reich L; Barakat R; Curtin J; Moore MA; Hoskins W
    J Clin Oncol; 1995 May; 13(5):1160-6. PubMed ID: 7537799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer.
    Fennelly DW; Aghajanian C; Shapiro F; O'Flaherty C; O'Connor K; Curtin JP; Crown JP; Hoskins WJ; Spriggs DR
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-26-S2-30. PubMed ID: 9045332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.
    Aghajanian C; Fennelly D; Shapiro F; Waltzman R; Almadrones L; O'Flaherty C; O'Conner K; Venkatraman E; Barakat R; Curtin J; Brown C; Reich L; Wuest D; Norton L; Hoskins W; Spriggs DR
    J Clin Oncol; 1998 May; 16(5):1852-60. PubMed ID: 9586901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer.
    Wandt H; Birkmann J; Denzel T; Schäfer K; Schwab G; Pilz D; Egger H; Both A; Gallmeier WM
    Bone Marrow Transplant; 1999 Apr; 23(8):763-70. PubMed ID: 10231137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study.
    Schilder RJ; Brady MF; Spriggs D; Shea T
    Gynecol Oncol; 2003 Jan; 88(1):3-8. PubMed ID: 12504619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer.
    Crown J; Kritz A; Vahdat L; Reich L; Moore M; Hamilton N; Schneider J; Harrison M; Gilewski T; Hudis C
    J Clin Oncol; 1993 Jun; 11(6):1144-9. PubMed ID: 7684770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer.
    Demirer T; Rowley S; Buckner CD; Appelbaum FR; Lilleby K; Storb R; Schiffman K; Bensinger WI
    J Clin Oncol; 1995 Jul; 13(7):1714-9. PubMed ID: 7541450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer.
    Ford C; Spitzer G; Reilly W; Adkins D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-81-S17-86. PubMed ID: 9374101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer.
    Vahdat L; Raptis G; Fennelly D; Hamilton N; Reich L; Tiersten A; Harrison M; Hudis C; Moore M; Yao TJ; Norton L; Crown J
    Clin Cancer Res; 1995 Nov; 1(11):1267-73. PubMed ID: 9815921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
    Shea T; Graham M; Bernard S; Steagall A; Wiley J; Serody J; Brecher M; Bentley S; Johnston C; Vaisman A
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):80-5. PubMed ID: 7481867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
    Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.